(Q43037268)

12 November 2017

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients (English)

1 reference

12 November 2017

1 reference

6

Hiromitsu Kumada

1 reference

12 November 2017

Makoto Kuboki

1

1 reference

12 November 2017

Shiro Iino

2

1 reference

12 November 2017

Tadao Okuno

3

1 reference

12 November 2017

Masao Omata

4

1 reference

12 November 2017

Kendo Kiyosawa

5

1 reference

12 November 2017

Norio Hayashi

7

1 reference

12 November 2017

Takahiro Sakai

8

1 reference

12 November 2017

language of work or name

1 reference

1 May 2007

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

1 reference

12 November 2017

22

1 reference

12 November 2017

5

1 reference

12 November 2017

645-652

1 reference

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Differences in treatment outcome for hepatitis C among ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04834.X

10.1111/J.1440-1746.2007.04834.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference